E7820

TargetMol
Product Code: TAR-T4435
Supplier: TargetMol
CodeSizePrice
TAR-T4435-1mg1mg£95.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4435-2mg2mg£106.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4435-5mg5mg£121.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4435-1mL1 mL * 10 mM (in DMSO)£132.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4435-10mg10mg£135.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4435-25mg25mg£189.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4435-50mg50mg£249.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4435-100mg100mg£357.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4435-200mg200mg£495.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
E7820 is an angiogenesis inhibitor by suppressing integrin a2 (a cell adhesion molecule expressed on endothelial cells).
CAS:
289483-69-8
Formula:
C17H12N4O2S
Molecular Weight:
336.37
Pathway:
Cytoskeletal Signaling
Purity:
0.9848
SMILES:
Cc1ccc(NS(=O)(=O)c2cccc(c2)C#N)c2[nH]cc(C#N)c12
Target:
Integrin

References

Keizer R J, Funahashi Y, Semba T, et al. Evaluation of ? 2-Integrin Expression as a Biomarker for Tumor Growth Inhibition for the Investigational Integrin Inhibitor E7820 in PreClinicalal and Clinicalal Studies[J]. The AAPS journal, 2011, 13(2): 230-239. Semba T, Funahashi Y, Ono N, et al. An angiogenesis inhibitor E7820 shows broad-spectrum tumor growth inhibition in a xenograft model: possible value of integrin ?2 on platelets as a biological marker[J]. Clinicalal Cancer Research, 2004, 10(4): 1430-1438. Ito K, Semba T, Uenaka T, et al. Enhanced anti?angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor?tyrosine kinase inhibitor?resistant non?small?cell lung cancer xenograft models[J]. Cancer science, 2014, 105(8): 1023-1031.